EUCTR2009-013407-66-HU进行中（未招募）不适用
A Rollover Protocol to Allow Continued Access to Tivozanib Hydrochloride (AV-951) for Subjects Enrolled in Other Tivozanib Hydrochloride Protocols
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject must have received tivozanib hydrochloride while enrolled in another protocol, must be tolerating study drug and must currently display clinical benefit. The length of time that a subject must be on the parent protocol before rolling over to this protocol will be dictated by the parent protocol.
- •a. Subjects who received tivozanib hydrochloride at any time while on parent protocol AV-951-12-205, regardless of sequence, may enroll if they tolerated and displayed clinical benefit while receiving tivozanib hydrochloride.
- •b. Subjects receiving sorafenib in Study AV-951-09-902 who were tolerating sorafenib and displaying clinical benefit at the time of study termination may initiate tivozanib hydrochloride as a treatment option.
- •2. If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment (i.e. before the first dose of tivozanib hydrochloride in this protocol).
- •3. Ability to give written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1
排除标准
- •1. > 4 weeks since discontinuation of study drug treatment on a previous AVEO-sponsored clinical trial.
- •a. For subjects initiating tivozanib hydrochloride (ie receiving sorafenib and demonstrating tolerability and clinical benefit on Study AV-951-09-902 at the time of study termination), > 4 weeks since last dose of sorafenib, unless discussed with Sponsor.
- •2. If female, pregnant or lactating.
- •3. Sexually active male and pre-menopausal female subjects (and their partners) unless they agree to use adequate contraceptive measures, while on study and for 45 days after the last dose of study drug. All fertile male and female subjects (and their partners) must agree to use a highly effective method of contraception. Highly effective birth control includes (a) IUD plus one barrier method; (b) oral, implantable or injectable contraceptive plus one barrier method; or (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm).
- •4. Uncontrolled hypertension: systolic blood pressure > 140 mmHg or diastolic blood pressure >90 mmHg documented on 2 consecutive measurements taken at least 24 hours apart.
- •5. Unhealed wounds (including active peptic ulcers).
- •6. Serious/active infection or infection requiring parenteral antibiotics.
- •7. Life-threatening illness or organ system dysfunction compromising safety evaluation.
- •8. Psychiatric disorder, altered mental status precluding informed consent or necessary testing.
- •9. Inability to comply with protocol requirements.
研究者
相似试验
进行中（未招募）
不适用
Study to continue giving Tivozanib to subjects participating in other studies with TivozanibRenal Cell CarcinomaMedDRA version: 16.1Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-013407-66-PLAVEO Pharmaceuticals, Inc.82
进行中（未招募）
不适用
A Protocol to Allow Continued Access to Tivozanib for Subjects Enrolled in Other Tivozanib Protocolsmetastatic renal cell carcinomaMedDRA version: 15.0Level: LLTClassification code 10038400Term: Renal carcinoma stage IVSystem Organ Class: 100000004864MedDRA version: 15.0Level: LLTClassification code 10038399Term: Renal carcinoma stage IIISystem Organ Class: 100000004864MedDRA version: 15.0Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2009-013407-66-ITAVEO PHARMACEUTICALS, INC.160
进行中（未招募）
不适用
Study to continue giving Tivozanib to subject participating in other studies with TivozanibRenal Cell CarcinomaEUCTR2009-013407-66-BGAVEO Pharmaceuticals, Inc.82
进行中（未招募）
不适用
Study to continue giving Tivozanib hydrochloride to subjects participating in other studies with Tivozanib hydrochlorideEUCTR2009-013407-66-GBAVEO Pharmaceuticals, Inc.
进行中（未招募）
1 期
Study to continue giving Tivozanib to subject participating in other studies with TivozanibRenal Cell Carcinoma Stage III, Renal Cell Carcinoma Stage IV, Metastatic Renal Cell Carcinoma,MedDRA version: 16.1Level: LLTClassification code 10038400Term: Renal carcinoma stage IVSystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10038399Term: Renal carcinoma stage IIISystem Organ Class: 100000004864MedDRA version: 16.1Level: LLTClassification code 10050076Term: Metastatic renal carcinomaSystem Organ Class: 100000004864EUCTR2009-013407-66-BEAVEO Pharmaceuticals, Inc.